Human cell chimerism in the bone marrow of newborn-engrafted mice at 12 weeks of age
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy, (N = 10) . | NSG, 0 cGy, (N = 8) . | NSG-Tg(hu-mSCF), 100 cGy, (N = 7) . | NSG, 100 cGy, (N = 10) . | ||||
|---|---|---|---|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 56.7 ± 22 | 12.6 ± 6.0* | 37.1 ± 21 | 4.7 ± 4.5† | 71.5 ± 8.1 | 6.4 ± 5.5 | 50.8 ± 16.3 | 10.6 ± 3.8 |
| B-cell lineage, % of CD45 | ||||||||
| CD20+ | 4.04 ± 1.7 | 6.75 ± 3.9 | 2.58 ± 1.4 | 3.92 ± 2.2 | ||||
| CD10+/20+ | 9.89 ± 5.1 | 18.6 ± 6.8 | 9.32 ± 6.4 | 8.54 ± 4.4 | ||||
| Myeloid/granulocytic, % of CD45 | ||||||||
| CD33+ | 4.21 ± 3.3 | 4.86 ± 2.9 | 9.41 ± 8.1 | 6.71 ± 3.8 | ||||
| CD33+/64+ | 5.10 ± 4.8 | 0.76 ± 0.61 | 6.56 ± 7.0 | 6.07 ± 7.5 | ||||
| CD14+ | 6.23 ± 5.7 | 2.79 ± 1.7 | 7.13 ± 6.5 | 7.32 ± 6.4 | ||||
| Dendritic cell subsets, % of CD45 | ||||||||
| CD11c+ | 0.93 ± 0.71 | 0.58 ± 0.33 | 1.00 ± 0.78 | 1.51 ± 1.67 | ||||
| CD123+ | 2.08 ± 1.9 | 3.70 ± 2.26 | 2.46 ± 1.9 | 1.92 ± 1.43 | ||||
| Hematopoietic progenitor, % of CD45 | ||||||||
| CD34+/CD38− | 0.27 ± 0.3 | 0.03 ± 0.03 | 0.43 ± 0.35 | 0.63 ± 0.46 | ||||
| CD34+/CD38+ | 3.85 ± 2.6 | 6.50 ± 3.3 | 5.47 ± 2.3 | 6.4 ± 3.9 | ||||
| Erythroblast/RBC, % of CD45 negative | ||||||||
| CD71+ | 2.17 ± 2.8 | 0.22 ± 0.18 | 1.62 ± 1.0 | 0.55 ± 0.60 | ||||
| CD71+/235a+ | 4.65 ± 5.7‡ | 0.13 ± 0.26 | 25.49 ± 22 | 0.60 ± 0.60 | ||||
| CD235a+ | 0.47 ± 0.6§ | 0.05 ± 0.02 | 3.30 ± 3.2 | 0.27 ± 0.31 | ||||
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy, (N = 10) . | NSG, 0 cGy, (N = 8) . | NSG-Tg(hu-mSCF), 100 cGy, (N = 7) . | NSG, 100 cGy, (N = 10) . | ||||
|---|---|---|---|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 56.7 ± 22 | 12.6 ± 6.0* | 37.1 ± 21 | 4.7 ± 4.5† | 71.5 ± 8.1 | 6.4 ± 5.5 | 50.8 ± 16.3 | 10.6 ± 3.8 |
| B-cell lineage, % of CD45 | ||||||||
| CD20+ | 4.04 ± 1.7 | 6.75 ± 3.9 | 2.58 ± 1.4 | 3.92 ± 2.2 | ||||
| CD10+/20+ | 9.89 ± 5.1 | 18.6 ± 6.8 | 9.32 ± 6.4 | 8.54 ± 4.4 | ||||
| Myeloid/granulocytic, % of CD45 | ||||||||
| CD33+ | 4.21 ± 3.3 | 4.86 ± 2.9 | 9.41 ± 8.1 | 6.71 ± 3.8 | ||||
| CD33+/64+ | 5.10 ± 4.8 | 0.76 ± 0.61 | 6.56 ± 7.0 | 6.07 ± 7.5 | ||||
| CD14+ | 6.23 ± 5.7 | 2.79 ± 1.7 | 7.13 ± 6.5 | 7.32 ± 6.4 | ||||
| Dendritic cell subsets, % of CD45 | ||||||||
| CD11c+ | 0.93 ± 0.71 | 0.58 ± 0.33 | 1.00 ± 0.78 | 1.51 ± 1.67 | ||||
| CD123+ | 2.08 ± 1.9 | 3.70 ± 2.26 | 2.46 ± 1.9 | 1.92 ± 1.43 | ||||
| Hematopoietic progenitor, % of CD45 | ||||||||
| CD34+/CD38− | 0.27 ± 0.3 | 0.03 ± 0.03 | 0.43 ± 0.35 | 0.63 ± 0.46 | ||||
| CD34+/CD38+ | 3.85 ± 2.6 | 6.50 ± 3.3 | 5.47 ± 2.3 | 6.4 ± 3.9 | ||||
| Erythroblast/RBC, % of CD45 negative | ||||||||
| CD71+ | 2.17 ± 2.8 | 0.22 ± 0.18 | 1.62 ± 1.0 | 0.55 ± 0.60 | ||||
| CD71+/235a+ | 4.65 ± 5.7‡ | 0.13 ± 0.26 | 25.49 ± 22 | 0.60 ± 0.60 | ||||
| CD235a+ | 0.47 ± 0.6§ | 0.05 ± 0.02 | 3.30 ± 3.2 | 0.27 ± 0.31 | ||||
Nonirradiated NSG and NSG-Tg(hu-mSCF) newborn mice, and 100-cGy irradiated NSG and NSG-Tg(hu-mSCF) newborn mice were engrafted with human HSCs as described in “Engraftment of mice with human HSCs.” Mice were analyzed by flow cytometry for the percentage and number of human CD45+ and the percentage of human CD45+ cells that were positive for specific lineage markers in the bone marrow at 12 weeks of age. Data are mean ± SD. Significant differences were observed in the number of human CD45+ cells.
Nonirradiated NSG-Tg(hu-mSCF) vs nonirradiated NSG (P < .01).
Nonirradiated NSG vs 100 cGy irradiated NSG (P < .01).
Nonirradiated NSG-Tg(hu-mSCF) vs nonirradiated and 100 cGy irradiated NSG (P < .05).
Nonirradiated NSG-Tg(hu-mSCF) vs nonirradiated NSG (P < .05).